Hutchmed (china) Share Discussion Threads

[nerdofsteel] 01/12/2018 10:59

Lots sold but charts are very bullish at the moment with hammer candlestick

[dbadvn] 30/11/2018 22:31

Question is where did all that stock come from without driving the price up more?

[nerdofsteel] 30/11/2018 22:16

6.03 million ADR's traded on NASDAQ today, circa $207m worth of stock. That is unprecedented, I do not recall seeing that level of trading since the first IPO.

[lauders] 29/11/2018 22:57

Thanks for your LSE post here too NofS.

The Taizhou link worked fine at home so nice to see 3x websites working.

[nerdofsteel] 29/11/2018 16:33

Great work Lauders and to add, here's my LSE post from this morning:-

1. Shanghai Junshi appears to be in the process of a HK IPO
2. Innovent Biologics - IPO'd in HK in early Nov
3. Taizhou Hanzhong Pharmaceuticals - private
4. Genor Biopharma - private (majority owned buy Hill House Capital)

[lauders] 29/11/2018 11:34

Some news arrived anyway and it is all adding to the build blocks of the future. If any of these collaborations produce anything really meaningful it will just add more value to HCM than we believe at possible at present. Not too impressed that Shanghai Junshi Biosciences Co. Ltd's website doesn't seem to open for me. Found this though:

Will take some reading!

Innovent Biologics (Suzhou) Co. Ltd's website looks more promising!

Will have to try the link for Taizhou Hanzhong Pharmaceuticals, Inc again at home. Doesn't want to open for me at the moment:

Genor Biopharma Co. Ltd's website looks more promising:

So two hits and two misses re: websites. Perhaps a bit like the chances of success with the collaboration efforts?

[mad foetus] 29/11/2018 08:03

Cheeky timing!

[lauders] 29/11/2018 01:13

We still have these 2 important updates to come within the next 4 weeks:-

1. Initiation of a global study of savolitinib/ Tagrisso® combo in 2L/3L NSCLC post Tagrisso® failure; AZ presents data on c-Met resistance; regulatory dialogue;

2. Molecular epidemiology study (n>200) in PRCC [3] – possibly BTD enabling

Would be very nice if we received positive news on one of these today NofS. With a nice rise in the US the momentum would really continue with luck. Then there is the MSCI entry at close of business tomorrow too, so next week could be interesting!

[nerdofsteel] 26/11/2018 11:06

$HCM being added to the Morgan Stanley China Index on 30th Nov, should result in buying by Funds that track the index

[lauders] 26/11/2018 09:07

Nice news that we knew was coming, but still nice to see confirmed. Now let's see what our US friends make of it when they return from their Thanksgiving break. Hopefully they will be in a good mood ;-)

[nerdofsteel] 26/11/2018 07:41

Commercial launch of Elunate - our first ever oncology drug has started shipping

[nerdofsteel] 24/11/2018 07:55

We still have these 2 important updates to come within the next 4 weeks:-

1. Initiation of a global study of savolitinib/ Tagrisso® combo in 2L/3L NSCLC post Tagrisso® failure; AZ presents data on c-Met resistance; regulatory dialogue;

2. Molecular epidemiology study (n>200) in PRCC [3] – possibly BTD enabling

[nerdofsteel] 21/11/2018 16:07

I'll assist with the sp, I'll be making another large purchase next week ;o-)

[steeplejack] 21/11/2018 08:27

They invariably do.In fact,shares often rise ahead of index inclusion only to fall thereafter studies show.

[lauders] 21/11/2018 00:55

Hopefully the post-disappointing results drop is now being taken advantage of by long term forward-thinking institutions who are picking up shares prior to the 30th November MSCI Index entry. It could actually be an interesting end to the month and start to December.

[nerdofsteel] 20/11/2018 09:24

MSCI Index - HCM added on the 30th Nov as picked up by miti on LSE

hxxps://app2.msci.com/eqb/gimi/stdindex/MSCI_Nov18_OVCPublicList.pdf

I wonder if funds & the main ETF started to build a position ahead of the 30th...

[nerdofsteel] 18/11/2018 09:29

Thanks Lauders, very interesting

Just a reminder for everyone we have these updates to come, and many regard Savolitinib as the drug with the biggest global potential:-

1. Initiate global study of savolitinib/ Tagrisso® combo in 2L NSCLC – regulatory & potential BTD [1] dialogue [2];

2.Initiate global study of savolitinib/ Tagrisso® combo in 2L/3L NSCLC post Tagrisso® failure; AZ presents data on c-Met resistance; regulatory dialogue;

3.Molecular epidemiology study (n>200) in PRCC [3] – possibly BTD enabling.

Epitinib
1. Initiate China Phase III study in 1L EGFRm NSCLC w/ brain mets.

Any positive updates on BTD for Savolitinib will probably have a positive impact

[lauders] 17/11/2018 00:56

Hopefully we can recover some ground over the next few weeks/months. Found this bit that explains the earlier rise before the disappointing news came our way:

Fellow drugmaker Hutchison China Meditech dropped after its lung cancer treatment failed a late-stage trial.

The tightly held stock, whose £3bn valuation makes it Aim’s second-biggest company, had surged this week after being added to MSCI’s China benchmark.



That is confirmed here where HCM is included within the list of "China Small Cap Index" additions:

[steeplejack] 16/11/2018 21:03

Not too bad Stateside,closed above $30 which is good.

[dbadvn] 16/11/2018 17:32

Definitely not a mess. Upside value by analysts was limited recognising that this was a very long shot. I think that rather than casting doubt on the Chinese regulatory process this event shows that it has integrity.

Plenty more news to come relatively soon.

[nerdofsteel] 16/11/2018 12:01

The Co's pipeline is huge......

We have these to look forward to before the end of the year.......hopefully positive, I am particularly excited about the possibility of BTD for PRCC

1. Initiate global study of savolitinib/ Tagrisso® combo in 2L/3L NSCLC post Tagrisso® failure; AZ presents data on c-Met resistance; regulatory dialogue;

2. Molecular epidemiology study (n>200) in PRCC [3] – possibly BTD enabling.

My holding is into 5 figures in terms of numbers of shares, although a little behind Miti but I will catch up at some point ;o-)

[lauders] 16/11/2018 11:08

Quite miti 1000! Whether you believe what the IC say or not here is their take on the news:

IC TIP UPDATES:

It’s been a morning of clinical trial failures across the pharmaceutical industry, but one of the biggest casualties is Hutchison China Meditech (HCM), which has revealed its final-phase trial of fruquintinib in China has failed to demonstrate “a statistically significant increase in overall survival” amongst advanced non-small cell lung cancer patients. This marked one of four important drug trials for Chi-Med, as it hopes to build on fruquintinib’s commercial launch (the drug has already been approved to treat advanced colorectal cancer). It’s a big disappointment - evident in the 15 per cent share price drop in early trading - but chairman Simon To says he still has long-term faith in the drug, as well as the other trials currently underway. We see this morning’s de-rating as a second buying opportunity.

Also note the AZ news today and the IC's feedback on the same page.

[miti 1000] 16/11/2018 10:36

Hardly a mess , surely ?